Sutro Biopharma (STRO) Competitors

$27.76 -2.86 (-9.34%)

As of 01:57 PM Eastern

STRO vs. IRON, ELVN, NBTX, IDYA, and RARE

Should you buy Sutro Biopharma stock or one of its competitors? MarketBeat compares Sutro Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sutro Biopharma include Disc Medicine (IRON), Enliven Therapeutics (ELVN), Nanobiotix (NBTX), IDEAYA Biosciences (IDYA), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry.

How does Sutro Biopharma compare to Disc Medicine?

Sutro Biopharma (NASDAQ:STRO) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Disc Medicine has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-154.21%	N/A	-69.20%
Disc Medicine	N/A	-36.94%	-33.88%

In the previous week, Sutro Biopharma had 14 more articles in the media than Disc Medicine. MarketBeat recorded 20 mentions for Sutro Biopharma and 6 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.89 beat Sutro Biopharma's score of -0.12 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Disc Medicine	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sutro Biopharma currently has a consensus price target of $48.25, indicating a potential upside of 70.80%. Disc Medicine has a consensus price target of $105.30, indicating a potential upside of 56.94%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, research analysts plainly believe Sutro Biopharma is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Sutro Biopharma has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	4.57	-$191.09M	-$11.04	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 3.6% of Sutro Biopharma shares are owned by company insiders. Comparatively, 3.8% of Disc Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Sutro Biopharma has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Summary

Sutro Biopharma beats Disc Medicine on 10 of the 16 factors compared between the two stocks.

How does Sutro Biopharma compare to Enliven Therapeutics?

Sutro Biopharma (NASDAQ:STRO) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

In the previous week, Sutro Biopharma had 19 more articles in the media than Enliven Therapeutics. MarketBeat recorded 20 mentions for Sutro Biopharma and 1 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.00 beat Sutro Biopharma's score of -0.12 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enliven Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sutro Biopharma has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

97.0% of Sutro Biopharma shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 3.6% of Sutro Biopharma shares are held by insiders. Comparatively, 25.9% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sutro Biopharma currently has a consensus target price of $48.25, indicating a potential upside of 70.80%. Enliven Therapeutics has a consensus target price of $58.40, indicating a potential upside of 40.27%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, research analysts plainly believe Sutro Biopharma is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Enliven Therapeutics has lower revenue, but higher earnings than Sutro Biopharma. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	4.57	-$191.09M	-$11.04	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Enliven Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-154.21%	N/A	-69.20%
Enliven Therapeutics	N/A	-21.04%	-20.41%

Summary

Sutro Biopharma beats Enliven Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Sutro Biopharma compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Sutro Biopharma (NASDAQ:STRO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Nanobiotix has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market.

Nanobiotix currently has a consensus price target of $26.67, suggesting a potential downside of 35.86%. Sutro Biopharma has a consensus price target of $48.25, suggesting a potential upside of 70.80%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Sutro Biopharma is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

Nanobiotix has higher earnings, but lower revenue than Sutro Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	54.71	-$27.11M	N/A	N/A
Sutro Biopharma	$102.48M	4.57	-$191.09M	-$11.04	N/A

Nanobiotix has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Sutro Biopharma	-154.21%	N/A	-69.20%

In the previous week, Sutro Biopharma had 7 more articles in the media than Nanobiotix. MarketBeat recorded 20 mentions for Sutro Biopharma and 13 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.20 beat Sutro Biopharma's score of -0.12 indicating that Nanobiotix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sutro Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 3.6% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Sutro Biopharma beats Nanobiotix on 9 of the 14 factors compared between the two stocks.

How does Sutro Biopharma compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Sutro Biopharma (NASDAQ:STRO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 3.6% of Sutro Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

IDEAYA Biosciences has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Sutro Biopharma	-154.21%	N/A	-69.20%

IDEAYA Biosciences has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.63, suggesting that its stock price is 63% more volatile than the broader market.

In the previous week, Sutro Biopharma had 19 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 20 mentions for Sutro Biopharma and 1 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 1.57 beat Sutro Biopharma's score of -0.12 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Sutro Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IDEAYA Biosciences presently has a consensus target price of $50.69, indicating a potential upside of 73.21%. Sutro Biopharma has a consensus target price of $48.25, indicating a potential upside of 70.80%. Given IDEAYA Biosciences' higher probable upside, equities research analysts plainly believe IDEAYA Biosciences is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

IDEAYA Biosciences has higher revenue and earnings than Sutro Biopharma. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	11.76	-$113.70M	-$1.60	N/A
Sutro Biopharma	$102.48M	4.57	-$191.09M	-$11.04	N/A

Summary

IDEAYA Biosciences beats Sutro Biopharma on 11 of the 17 factors compared between the two stocks.

How does Sutro Biopharma compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Sutro Biopharma (NASDAQ:STRO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Ultragenyx Pharmaceutical has a net margin of -91.03% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Sutro Biopharma	-154.21%	N/A	-69.20%

In the previous week, Sutro Biopharma had 12 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 20 mentions for Sutro Biopharma and 8 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.59 beat Sutro Biopharma's score of -0.12 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sutro Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 3.6% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ultragenyx Pharmaceutical has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market.

Ultragenyx Pharmaceutical currently has a consensus price target of $59.88, indicating a potential upside of 154.02%. Sutro Biopharma has a consensus price target of $48.25, indicating a potential upside of 70.80%. Given Ultragenyx Pharmaceutical's higher possible upside, equities research analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

Sutro Biopharma has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.45	-$575M	-$6.11	N/A
Sutro Biopharma	$102.48M	4.57	-$191.09M	-$11.04	N/A

Summary

Ultragenyx Pharmaceutical beats Sutro Biopharma on 9 of the 17 factors compared between the two stocks.

Get Sutro Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STRO vs. The Competition

Export

Metric	Sutro Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$467.44M	$3.38B	$6.38B	$12.34B
Dividend Yield	N/A	2.30%	2.79%	5.33%
P/E Ratio	-2.56	19.04	20.91	25.65
Price / Sales	4.57	298.20	543.80	85.61
Price / Cash	N/A	129.82	44.13	56.16
Price / Book	-6.99	6.98	10.09	7.06
Net Income	-$191.09M	$24.45M	$3.55B	$335.04M
7 Day Performance	-27.51%	3.54%	4.71%	2.60%
1 Month Performance	-20.49%	-0.26%	1.43%	1.42%
1 Year Performance	212.98%	62.90%	36.72%	35.67%

Sutro Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STRO Sutro Biopharma	3.0401 of 5 stars	$27.76 -9.3%	$48.25 +73.8%	+265.3%	$459.75M	$102.48M	N/A	240	Analyst Revision High Trading Volume
IRON Disc Medicine	2.3893 of 5 stars	$66.85 0.0%	$105.30 +57.5%	+37.3%	$2.55B	N/A	N/A	30
ELVN Enliven Therapeutics	2.613 of 5 stars	$39.63 -4.1%	$58.40 +47.4%	+149.6%	$2.52B	N/A	N/A	50
NBTX Nanobiotix	2.4426 of 5 stars	$49.48 -3.9%	$26.67 -46.1%	+970.0%	$2.50B	$36.87M	N/A	100	News Coverage Analyst Revision Gap Up
IDYA IDEAYA Biosciences	3.5375 of 5 stars	$28.32 +0.4%	$50.69 +79.0%	+54.3%	$2.48B	$218.71M	N/A	80	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STRO) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sutro Biopharma (STRO) Competitors

STRO vs. IRON, ELVN, NBTX, IDYA, and RARE

How does Sutro Biopharma compare to Disc Medicine?

Summary

How does Sutro Biopharma compare to Enliven Therapeutics?

Summary

How does Sutro Biopharma compare to Nanobiotix?

Summary

How does Sutro Biopharma compare to IDEAYA Biosciences?

Summary

How does Sutro Biopharma compare to Ultragenyx Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STRO vs. The Competition

Sutro Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sutro Biopharma (STRO) Competitors

STRO vs. IRON, ELVN, NBTX, IDYA, and RARE

How does Sutro Biopharma compare to Disc Medicine?

Is STRO or IRON more profitable?

Does the media prefer STRO or IRON?

Do analysts recommend STRO or IRON?

Which has higher earnings and valuation, STRO or IRON?

Do institutionals & insiders believe in STRO or IRON?

Which has more risk and volatility, STRO or IRON?

Summary

How does Sutro Biopharma compare to Enliven Therapeutics?

Does the media refer more to STRO or ELVN?

Which has more risk and volatility, STRO or ELVN?

Do institutionals and insiders believe in STRO or ELVN?

Do analysts rate STRO or ELVN?

Which has higher valuation & earnings, STRO or ELVN?

Is STRO or ELVN more profitable?

Summary

How does Sutro Biopharma compare to Nanobiotix?

Which has more risk and volatility, NBTX or STRO?

Do analysts prefer NBTX or STRO?

Which has better valuation and earnings, NBTX or STRO?

Is NBTX or STRO more profitable?

Does the media prefer NBTX or STRO?

Do institutionals & insiders hold more shares of NBTX or STRO?

Summary

How does Sutro Biopharma compare to IDEAYA Biosciences?

Do institutionals and insiders believe in IDYA or STRO?

Is IDYA or STRO more profitable?

Which has more volatility & risk, IDYA or STRO?

Does the media favor IDYA or STRO?

Do analysts rate IDYA or STRO?

Which has preferable valuation and earnings, IDYA or STRO?

Summary

How does Sutro Biopharma compare to Ultragenyx Pharmaceutical?

Is RARE or STRO more profitable?

Does the media favor RARE or STRO?

Do insiders and institutionals hold more shares of RARE or STRO?

Which has more volatility & risk, RARE or STRO?

Do analysts prefer RARE or STRO?

Which has preferable valuation & earnings, RARE or STRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STRO vs. The Competition

Sutro Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools